Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 84 (6) , 594-598
- https://doi.org/10.1016/s1081-1206(10)62409-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Detection of Mycoplasma pneumoniae in the Airways of Adults with Chronic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthmaClinical and Experimental Allergy, 1998
- Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5Journal of Allergy and Clinical Immunology, 1996
- Eosinophil activity markers in peripheral blood have high predictive value for bronchial hyperreactivity in patients with suspected mild asthmaAllergy, 1996
- Evaluation of serum eosinophilic cationic protein as a marker of disease activity in chronic asthmaJournal of Allergy and Clinical Immunology, 1995
- The evaluation of a cell dispersion method of sputum examinationClinical and Experimental Allergy, 1994
- The relationship between inflammation and hyperreactivity of the airways in asthmaClinical and Experimental Allergy, 1993
- Erythromycin Reduces the Severity of Bronchial Hyperresponsiveness in Asthma*Chest, 1991
- Statement on Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and AsthmaAmerican Review of Respiratory Disease, 1987
- Inhibition of methylprednisolone elimination in the presence of erythromycin therapyJournal of Allergy and Clinical Immunology, 1983